Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | FGFR3 Y373C |
| Gene Variant Detail | |
| Relevant Treatment Approaches | FGFR Inhibitor (Pan) FGFR3 Inhibitor |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05627063 | Phase I | ABSK121 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 1 |
| NCT05564416 | Phase II | Erdafitinib Atezolizumab + Erdafitinib | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial | Withdrawn | 0 | |
| NCT04917809 | Phase II | Erdafitinib | A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer | Active, not recruiting | USA | 0 |